WHO approves GLP-1s for some obese youth: what Canadian clinicians and PCOS patients need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

The World Health Organization (WHO) released its first-ever international guidelines on childhood obesity on October 7, 2026, conditionally endorsing GLP-1 receptor agonist medications for youth aged 10 to 19 when supervised lifestyle programs have not produced results. For Canadian families and clinicians, the guidelines land on already-familiar ground: Health Canada has approved two GLP-1 medications for weight management in adolescents aged 12 and older, but provincial drug plans across the country have been slow to cover them, meaning most young patients pay through private insurance or entirely out of pocket.

The WHO guidance covers roughly 170 million children and teens globally who were living with obesity in 2024, a figure the agency says has quadrupled since 1990. For a Canadian patient or parent reading this, the practical question is whether the WHO's endorsement will accelerate public funding. Dr. Marina Ybarra, a pediatric endocrinologist at London Health Sciences Centre Children's Hospital and Western University, told CBC News she hopes it will: "Maybe that will help us to get funding through the public system in Canada for children living with obesity. That's my biggest hope."

What this means in Canada

Health Canada has approved semaglutide (sold in Canada as Ozempic and Wegovy) and liraglutide (sold as Saxenda) for use in adolescents aged 12 and older for weight management, predating the WHO guidance. A generic semaglutide injection for weight loss was also approved by Health Canada in 2026, which may reduce costs over time.

Despite federal approval, provincial and territorial drug plans, including OHIP in Ontario, RAMQ in Quebec, MSP in British Columbia, and AHCIP in Alberta, do not broadly list GLP-1s for pediatric obesity indications. Coverage, where it exists, is typically tied to type 2 diabetes diagnoses rather than obesity alone. Canada's national pharmacare framework, still being implemented as of late 2026, has prioritized diabetes and cardiovascular medications in its first formulary and has not yet addressed pediatric obesity indications.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) has not issued a specific position statement on GLP-1 use in adolescents with obesity or polycystic ovary syndrome (PCOS). The Canadian Medical Association Journal (CMAJ) published updated Canadian pediatric obesity guidelines in 2025, and those guidelines take a notably different stance from the WHO: they do not require that lifestyle interventions fail before medication is considered. The CMAJ guidance states plainly that "there is no evidence to support a stepwise approach whereby pharmacologic and surgical interventions should be offered only if behavioural and psychological interventions prove ineffective," and calls for shared decision-making with families.

For adolescents with PCOS, a condition that frequently co-occurs with insulin resistance and weight gain, GLP-1s are an area of active clinical interest. No Canadian regulatory body has issued PCOS-specific guidance on GLP-1 use in youth as of this writing.

What changed

The WHO's October 2026 guidelines are the first time the agency has formally addressed medication as a tool in childhood obesity management at a global level. The organization draws a firm line at age nine: no medication, surgery, or weight-loss devices for children up to that age. For youth 10 to 19, medication may be considered only after a supervised lifestyle program has not achieved results. Bariatric surgery is reserved for severe obesity under strict conditions.

This is more conservative than the 2025 CMAJ guidelines, which set the age threshold at 12 and do not require lifestyle-program failure as a prerequisite. The WHO's caution reflects what it describes as evidence that is "generally of low quality due to short-term follow-up" and small study populations.

A study published in the journal Pediatrics in September 2026 documented a 310-fold increase in GLP-1 prescriptions for children aged 8 to 11 in the United States between 2019 and 2026, rising from 0.03 percent to over nine percent of that age group. Overall use in younger children remains rare, but the trend has drawn attention from regulators and clinicians on both sides of the border.

Drug trials for children as young as six are currently underway by Novo Nordisk (Denmark) and Eli Lilly (US). The WHO declined to speculate on how trial results might alter its recommendations.

What Canadian patients should know

If your child or teenager is living with obesity and you are considering a GLP-1, the starting point is a referral to a pediatric endocrinologist or a specialized pediatric weight management clinic. Clinics like the London Health Sciences Centre Children's Hospital program exist in several provinces, though wait times vary.

For adolescents with PCOS specifically, GLP-1s are sometimes prescribed off-label to address insulin resistance and weight. Discuss this with a reproductive endocrinologist or a gynecologist familiar with PCOS management. Canadian telehealth platforms such as Maple and Telus Health can facilitate initial consultations, though prescribing decisions for minors typically require in-person specialist involvement. Science & Humans (scienceandhumans.com) offers hormone-related care for adults but does not serve pediatric patients.

On cost: without provincial coverage, branded Wegovy or Saxenda can run several hundred Canadian dollars per month. The arrival of generic semaglutide in Canada in 2026 may bring prices down, but generic pediatric dosing data are still limited. Check whether your employer's benefits plan covers GLP-1s for weight management, as plan language varies widely.

The WHO guidelines do not change what Health Canada has approved or what provincial plans cover. They may, however, strengthen the case that physicians and patient advocates make to provincial formulary committees.

Limitations and open questions

Long-term safety data for GLP-1 use in children and adolescents are thin. Dr. Ybarra acknowledged this directly, noting that while short-term data are reassuring, the drugs are simply too new in younger populations to have robust follow-up evidence. The WHO's own review rated the overall evidence quality as low.

The WHO guidelines do not address PCOS as a distinct indication, and neither the SOGC nor Health Canada has issued guidance specific to GLP-1 use in adolescents with PCOS. The potential for misuse in athletes or in youth with eating disorders is a concern the WHO flagged explicitly, and clinicians screening candidates should assess for these risk factors.

Provincial coverage decisions are made independently and on their own timelines. Whether the WHO endorsement accelerates any formulary reviews in Ontario, Quebec, British Columbia, or Alberta is unknown.

Trials in children under 10 are ongoing. Until those results are published and reviewed by Health Canada, no approved pathway exists for that age group in Canada.

---

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.